Antimicrobial resistance in faecal Escherichia coli isolates from horses treated with antimicrobials: a longitudinal study in hospitalised and non-hospitalised horses

Veterinary Microbiology
Imogen JohnsAndrew Rycroft

Abstract

The objective of this study was to examine the emergence and persistence of antimicrobial resistant faecal Escherichia coli in horses treated with antimicrobial drugs in a hospital and community setting. Faecal samples were collected from hospitalised (n=56) and non-hospitalised (n=14) horses treated with antimicrobials, and 10 non-treated hospitalised controls. Samples were obtained pre-treatment and 5 days later in all horses, and 2 weeks and 2 months after treatment in treated horses. Susceptibility to 15 antimicrobials was tested via disc diffusion on up to 3 E. coli isolates per sample. Phenotypic extended spectrum beta-lactamase (ESBL) production was identified via a combination disc method, and ESBL-encoding sequences identified by PCR. A resistant E. coli isolate was identified in 138/228 (60.5%) samples. The proportion of resistant samples was not significantly different between hospitalised and non-hospitalised treated horses. The odds of a sample containing a resistant isolate increased significantly at day 5 in treated horses, but not in controls. Two weeks following treatment, the odds of resistance in non-hospitalised horses returned to pre-treatment levels, but remained significantly above pre-treatment levels in...Continue Reading

References

Jan 1, 1995·Antimicrobial Agents and Chemotherapy·C LévesqueP H Roy
Jun 19, 2001·Lancet·O CarsA Melander
Nov 5, 2004·Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health·K Mølbak
Apr 28, 2005·Antimicrobial Agents and Chemotherapy·Mitchell J SchwaberYehuda Carmeli
Sep 10, 2005·Applied and Environmental Microbiology·Patrick F McDermottDavid D Wagner
Feb 4, 2006·Veterinary Microbiology·E ThomasC Wilhelm
Dec 24, 2008·Animal Health Research Reviews·Patrick Boerlin, Richard J Reid-Smith
Jan 1, 2010·Irish Veterinary Journal·Jill BryanVivienne Duggan

❮ Previous
Next ❯

Citations

Jun 19, 2015·Equine Veterinary Journal·T W MaddoxG L Pinchbeck
Aug 21, 2015·Journal of Veterinary Internal Medicine·L J Toombs-RuaneS M Rosanowski
Jan 30, 2015·The Veterinary Record·I C Johns, E-L Adams
Feb 3, 2018·Equine Veterinary Journal·D I Rendle, S W Page
Nov 21, 2017·Journal of the American Veterinary Medical Association·UNKNOWN National Association of State Public Health Veterinarians Animal Contact Compendium CommitteeMary Grace Stobierski
Sep 16, 2018·The Veterinary Record
Dec 19, 2019·Journal of Veterinary Internal Medicine·Julie F N Potier, Andy E Durham
Feb 15, 2020·Animals : an Open Access Journal From MDPI·Anat Shnaiderman-TorbanAmir Steinman
Aug 6, 2019·Frontiers in Microbiology·Filipa Trigo da RozaManuela Oliveira
Apr 27, 2021·Critical Reviews in Microbiology·Scott MitchellNicholas V Coleman
Mar 19, 2019·Journal of Global Antimicrobial Resistance·Rachel DuchesneAlbertine Leon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.